AZD4017 ( DrugBank: AZD-4017 )


1 disease
IDDisease name (Link within this page)Number of trials
75Cushing disease2

75. Cushing disease


Clinical trials : 203 Drugs : 191 - (DrugBank : 51) / Drug target genes : 62 - Drug target pathways : 128
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03111810
(ClinicalTrials.gov)
May 25, 201717/3/2017Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 InhibitionTargeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)Iatrogenic Cushing's DiseaseDrug: AZD4017 and prednisolone;Drug: Placebo Oral Tablet and prednisoloneUniversity of OxfordAstraZenecaCompleted18 Years60 YearsMale32Phase 2United Kingdom
2EUCTR2016-003060-40-GB
(EUCTR)
17/01/201722/12/2016Treating side effects of steroid medicationTargeting Iatrogenic Cushing’s Syndrome with 11ß-hydroxysteroid dehydrogenase type 1 Inhibition - TICSI version 0.6 Adverse effects of prescribed glucocorticoid therapy
MedDRA version: 19.0;Level: LLT;Classification code 10068501;Term: Cushing's syndrome, steroid-induced;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Product Name: AZD4017
Product Code: AZD4017
INN or Proposed INN: no INN available
Other descriptive name: AZD4017
University of Oxford, Clinical Trials and Research GovernanceNULLNot RecruitingFemale: no
Male: yes
32Phase 2United Kingdom